Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
2016
AbstractHypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves glycemic control and systolic blood pressure (SBP) in T2DM patients. This double-blind phase III study evaluated the effects of dapagliflozin on glycemic control and blood pressure in patients with inadequately controlled T2DM and hypertension, despite ongoing therapy with a renin–angiotensin system blocker. Patients were randomized to receive dapagliflozin 10 mg (n = 302) or placebo (n = 311) once daily for 12 weeks. Endpoints were change from baseline to week 12 in seated SBP and glycosylated hemoglobin (HbA1c); longitudinal repeated-measures analysis was performed. Additional endpoints included other hemodynamic measures, serum uric acid, fasting plasma glucose, body weight, blood lipids and heart rate. After 12 weeks, dapagliflozin-treated versus placebo-treated patients showed significant reductions in HbA1c (–0.6% vs –0.1%, p < 0.0001), mean seated SBP (–10.4 vs –7.3 mmHg, p =...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
62
Citations
NaN
KQI